Barzolvolimab (CDX 0159) is a humanized IgG1 monoclonal antibody targeting the KIT receptor. It demonstrates specificity and potent inhibition of KIT activation mediated by the stem cell factor (SCF). Clinically, Barzolvolimab has been shown to effectively reduce skin mast cell populations and alleviate disease activity in chronic inducible urticaria, highlighting its potential therapeutic application in related pathologies.
Barzolvolimab (CDX 0159) is a humanized IgG1 monoclonal antibody targeting the KIT receptor. It demonstrates specificity and potent inhibition of KIT activation mediated by the stem cell factor (SCF). Clinically, Barzolvolimab has been shown to effectively reduce skin mast cell populations and alleviate disease activity in chronic inducible urticaria, highlighting its potential therapeutic application in related pathologies.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
